Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Shares Outstanding (Diluted Average) (2022 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $40.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 4.05% year-over-year to $40.7 million, compared with a TTM value of $40.7 million through Sep 2025, up 4.05%, and an annual FY2024 reading of $39.3 million, up 2.51% over the prior year.
  • Shares Outstanding (Diluted Average) was $40.7 million for Q3 2025 at Barinthus Biotherapeutics, up from $40.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $40.7 million in Q3 2025 and bottomed at $38.0 million in Q1 2023.
  • Average Shares Outstanding (Diluted Average) over 4 years is $38.9 million, with a median of $38.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) dropped 0.13% in 2023, then grew 4.05% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $38.2 million in 2022, then increased by 0.57% to $38.4 million in 2023, then grew by 2.51% to $39.3 million in 2024, then rose by 3.34% to $40.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for BRNS at $40.7 million in Q3 2025, $40.3 million in Q2 2025, and $40.3 million in Q1 2025.